Many modules are hidden in this stack. Use "module --show_hidden spider SOFTWARE" if you are not able to find the required software
# packages in environment at /cluster/home/gcardenal/miniconda3/envs/vllm:
#
# Name                    Version                   Build  Channel
_libgcc_mutex             0.1                        main  
_openmp_mutex             5.1                       1_gnu  
accelerate                1.1.1                    pypi_0    pypi
aiohappyeyeballs          2.4.0                    pypi_0    pypi
aiohttp                   3.10.6                   pypi_0    pypi
aiosignal                 1.3.1                    pypi_0    pypi
annotated-types           0.7.0                    pypi_0    pypi
anthropic                 0.40.0                   pypi_0    pypi
anyio                     4.6.0                    pypi_0    pypi
argon2-cffi               23.1.0                   pypi_0    pypi
argon2-cffi-bindings      21.2.0                   pypi_0    pypi
arrow                     1.3.0                    pypi_0    pypi
asttokens                 3.0.0                    pypi_0    pypi
async-lru                 2.0.4                    pypi_0    pypi
async-timeout             4.0.3                    pypi_0    pypi
attrs                     24.2.0                   pypi_0    pypi
babel                     2.16.0                   pypi_0    pypi
beautifulsoup4            4.12.3                   pypi_0    pypi
bleach                    6.2.0                    pypi_0    pypi
bzip2                     1.0.8                h5eee18b_6  
ca-certificates           2024.7.2             h06a4308_0  
certifi                   2024.8.30                pypi_0    pypi
cffi                      1.17.1                   pypi_0    pypi
charset-normalizer        3.3.2                    pypi_0    pypi
click                     8.1.7                    pypi_0    pypi
cloudpickle               3.0.0                    pypi_0    pypi
comm                      0.2.2                    pypi_0    pypi
datasets                  3.0.1                    pypi_0    pypi
debugpy                   1.8.9                    pypi_0    pypi
decorator                 5.1.1                    pypi_0    pypi
defusedxml                0.7.1                    pypi_0    pypi
dill                      0.3.8                    pypi_0    pypi
diskcache                 5.6.3                    pypi_0    pypi
distro                    1.9.0                    pypi_0    pypi
einops                    0.8.0                    pypi_0    pypi
emoji                     2.14.0                   pypi_0    pypi
exceptiongroup            1.2.2                    pypi_0    pypi
executing                 2.1.0                    pypi_0    pypi
fastapi                   0.115.0                  pypi_0    pypi
fastjsonschema            2.21.1                   pypi_0    pypi
filelock                  3.16.1                   pypi_0    pypi
fqdn                      1.5.1                    pypi_0    pypi
frozenlist                1.4.1                    pypi_0    pypi
fsspec                    2024.6.1                 pypi_0    pypi
gguf                      0.10.0                   pypi_0    pypi
h11                       0.14.0                   pypi_0    pypi
httpcore                  1.0.5                    pypi_0    pypi
httptools                 0.6.1                    pypi_0    pypi
httpx                     0.27.2                   pypi_0    pypi
huggingface-hub           0.25.1                   pypi_0    pypi
idna                      3.10                     pypi_0    pypi
importlib-metadata        8.5.0                    pypi_0    pypi
interegular               0.3.3                    pypi_0    pypi
ipykernel                 6.29.5                   pypi_0    pypi
ipython                   8.30.0                   pypi_0    pypi
ipywidgets                8.1.5                    pypi_0    pypi
isoduration               20.11.0                  pypi_0    pypi
jedi                      0.19.2                   pypi_0    pypi
jinja2                    3.1.4                    pypi_0    pypi
jiter                     0.5.0                    pypi_0    pypi
json5                     0.10.0                   pypi_0    pypi
jsonpointer               3.0.0                    pypi_0    pypi
jsonschema                4.23.0                   pypi_0    pypi
jsonschema-specifications 2023.12.1                pypi_0    pypi
jupyter                   1.1.1                    pypi_0    pypi
jupyter-client            8.6.3                    pypi_0    pypi
jupyter-console           6.6.3                    pypi_0    pypi
jupyter-core              5.7.2                    pypi_0    pypi
jupyter-events            0.10.0                   pypi_0    pypi
jupyter-lsp               2.2.5                    pypi_0    pypi
jupyter-server            2.14.2                   pypi_0    pypi
jupyter-server-terminals  0.5.3                    pypi_0    pypi
jupyterlab                4.3.2                    pypi_0    pypi
jupyterlab-pygments       0.3.0                    pypi_0    pypi
jupyterlab-server         2.27.3                   pypi_0    pypi
jupyterlab-widgets        3.0.13                   pypi_0    pypi
lark                      1.2.2                    pypi_0    pypi
ld_impl_linux-64          2.40                 h12ee557_0  
libffi                    3.4.4                h6a678d5_1  
libgcc-ng                 11.2.0               h1234567_1  
libgomp                   11.2.0               h1234567_1  
libstdcxx-ng              11.2.0               h1234567_1  
libuuid                   1.41.5               h5eee18b_0  
llvmlite                  0.43.0                   pypi_0    pypi
lm-format-enforcer        0.10.6                   pypi_0    pypi
markupsafe                2.1.5                    pypi_0    pypi
matplotlib-inline         0.1.7                    pypi_0    pypi
mistral-common            1.4.3                    pypi_0    pypi
mistune                   3.0.2                    pypi_0    pypi
mpmath                    1.3.0                    pypi_0    pypi
msgpack                   1.1.0                    pypi_0    pypi
msgspec                   0.18.6                   pypi_0    pypi
multidict                 6.1.0                    pypi_0    pypi
multiprocess              0.70.16                  pypi_0    pypi
nbclient                  0.10.1                   pypi_0    pypi
nbconvert                 7.16.4                   pypi_0    pypi
nbformat                  5.10.4                   pypi_0    pypi
ncurses                   6.4                  h6a678d5_0  
nest-asyncio              1.6.0                    pypi_0    pypi
networkx                  3.3                      pypi_0    pypi
notebook                  7.3.1                    pypi_0    pypi
notebook-shim             0.2.4                    pypi_0    pypi
numba                     0.60.0                   pypi_0    pypi
numpy                     1.26.4                   pypi_0    pypi
nvidia-cublas-cu12        12.1.3.1                 pypi_0    pypi
nvidia-cuda-cupti-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-nvrtc-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-runtime-cu12  12.1.105                 pypi_0    pypi
nvidia-cudnn-cu12         9.1.0.70                 pypi_0    pypi
nvidia-cufft-cu12         11.0.2.54                pypi_0    pypi
nvidia-curand-cu12        10.3.2.106               pypi_0    pypi
nvidia-cusolver-cu12      11.4.5.107               pypi_0    pypi
nvidia-cusparse-cu12      12.1.0.106               pypi_0    pypi
nvidia-ml-py              12.560.30                pypi_0    pypi
nvidia-nccl-cu12          2.20.5                   pypi_0    pypi
nvidia-nvjitlink-cu12     12.6.68                  pypi_0    pypi
nvidia-nvtx-cu12          12.1.105                 pypi_0    pypi
openai                    1.48.0                   pypi_0    pypi
openssl                   3.0.15               h5eee18b_0  
outlines                  0.0.46                   pypi_0    pypi
overrides                 7.7.0                    pypi_0    pypi
packaging                 24.1                     pypi_0    pypi
pandas                    2.2.3                    pypi_0    pypi
pandocfilters             1.5.1                    pypi_0    pypi
parso                     0.8.4                    pypi_0    pypi
partial-json-parser       0.2.1.1.post4            pypi_0    pypi
pexpect                   4.9.0                    pypi_0    pypi
pillow                    10.4.0                   pypi_0    pypi
pip                       24.2            py310h06a4308_0  
platformdirs              4.3.6                    pypi_0    pypi
plotly                    5.24.1                   pypi_0    pypi
prometheus-client         0.21.0                   pypi_0    pypi
prometheus-fastapi-instrumentator 7.0.0                    pypi_0    pypi
prompt-toolkit            3.0.48                   pypi_0    pypi
protobuf                  5.28.2                   pypi_0    pypi
psutil                    6.0.0                    pypi_0    pypi
ptyprocess                0.7.0                    pypi_0    pypi
pure-eval                 0.2.3                    pypi_0    pypi
py-cpuinfo                9.0.0                    pypi_0    pypi
pyairports                2.1.1                    pypi_0    pypi
pyarrow                   17.0.0                   pypi_0    pypi
pycountry                 24.6.1                   pypi_0    pypi
pycparser                 2.22                     pypi_0    pypi
pydantic                  2.9.2                    pypi_0    pypi
pydantic-core             2.23.4                   pypi_0    pypi
pygments                  2.18.0                   pypi_0    pypi
python                    3.10.14              h955ad1f_1  
python-dateutil           2.9.0.post0              pypi_0    pypi
python-dotenv             1.0.1                    pypi_0    pypi
python-json-logger        2.0.7                    pypi_0    pypi
pytz                      2024.2                   pypi_0    pypi
pyyaml                    6.0.2                    pypi_0    pypi
pyzmq                     26.2.0                   pypi_0    pypi
ray                       2.37.0                   pypi_0    pypi
readline                  8.2                  h5eee18b_0  
referencing               0.35.1                   pypi_0    pypi
regex                     2024.9.11                pypi_0    pypi
requests                  2.32.3                   pypi_0    pypi
rfc3339-validator         0.1.4                    pypi_0    pypi
rfc3986-validator         0.1.1                    pypi_0    pypi
rpds-py                   0.20.0                   pypi_0    pypi
safetensors               0.4.5                    pypi_0    pypi
send2trash                1.8.3                    pypi_0    pypi
sentencepiece             0.2.0                    pypi_0    pypi
setuptools                75.1.0          py310h06a4308_0  
six                       1.16.0                   pypi_0    pypi
sniffio                   1.3.1                    pypi_0    pypi
soupsieve                 2.6                      pypi_0    pypi
sqlite                    3.45.3               h5eee18b_0  
stack-data                0.6.3                    pypi_0    pypi
stanza                    1.9.2                    pypi_0    pypi
starlette                 0.38.6                   pypi_0    pypi
sympy                     1.13.3                   pypi_0    pypi
tenacity                  9.0.0                    pypi_0    pypi
terminado                 0.18.1                   pypi_0    pypi
tiktoken                  0.7.0                    pypi_0    pypi
timm                      1.0.12                   pypi_0    pypi
tinycss2                  1.4.0                    pypi_0    pypi
tk                        8.6.14               h39e8969_0  
tokenizers                0.20.0                   pypi_0    pypi
tomli                     2.2.1                    pypi_0    pypi
torch                     2.4.0                    pypi_0    pypi
torchvision               0.19.0                   pypi_0    pypi
tornado                   6.4.2                    pypi_0    pypi
tqdm                      4.66.5                   pypi_0    pypi
traitlets                 5.14.3                   pypi_0    pypi
transformers              4.45.0                   pypi_0    pypi
triton                    3.0.0                    pypi_0    pypi
types-python-dateutil     2.9.0.20241003           pypi_0    pypi
typing-extensions         4.12.2                   pypi_0    pypi
tzdata                    2024.2                   pypi_0    pypi
uri-template              1.3.0                    pypi_0    pypi
urllib3                   2.2.3                    pypi_0    pypi
uvicorn                   0.30.6                   pypi_0    pypi
uvloop                    0.20.0                   pypi_0    pypi
vllm                      0.6.2                    pypi_0    pypi
watchfiles                0.24.0                   pypi_0    pypi
wcwidth                   0.2.13                   pypi_0    pypi
webcolors                 24.11.1                  pypi_0    pypi
webencodings              0.5.1                    pypi_0    pypi
websocket-client          1.8.0                    pypi_0    pypi
websockets                13.1                     pypi_0    pypi
wheel                     0.44.0          py310h06a4308_0  
widgetsnbextension        4.0.13                   pypi_0    pypi
xformers                  0.0.27.post2             pypi_0    pypi
xxhash                    3.5.0                    pypi_0    pypi
xz                        5.4.6                h5eee18b_1  
yarl                      1.12.1                   pypi_0    pypi
zipp                      3.20.2                   pypi_0    pypi
zlib                      1.2.13               h5eee18b_1  
Package                           Version
--------------------------------- --------------
accelerate                        1.1.1
aiohappyeyeballs                  2.4.0
aiohttp                           3.10.6
aiosignal                         1.3.1
annotated-types                   0.7.0
anthropic                         0.40.0
anyio                             4.6.0
argon2-cffi                       23.1.0
argon2-cffi-bindings              21.2.0
arrow                             1.3.0
asttokens                         3.0.0
async-lru                         2.0.4
async-timeout                     4.0.3
attrs                             24.2.0
babel                             2.16.0
beautifulsoup4                    4.12.3
bleach                            6.2.0
certifi                           2024.8.30
cffi                              1.17.1
charset-normalizer                3.3.2
click                             8.1.7
cloudpickle                       3.0.0
comm                              0.2.2
datasets                          3.0.1
debugpy                           1.8.9
decorator                         5.1.1
defusedxml                        0.7.1
dill                              0.3.8
diskcache                         5.6.3
distro                            1.9.0
einops                            0.8.0
emoji                             2.14.0
exceptiongroup                    1.2.2
executing                         2.1.0
fastapi                           0.115.0
fastjsonschema                    2.21.1
filelock                          3.16.1
fqdn                              1.5.1
frozenlist                        1.4.1
fsspec                            2024.6.1
gguf                              0.10.0
h11                               0.14.0
httpcore                          1.0.5
httptools                         0.6.1
httpx                             0.27.2
huggingface-hub                   0.25.1
idna                              3.10
importlib_metadata                8.5.0
interegular                       0.3.3
ipykernel                         6.29.5
ipython                           8.30.0
ipywidgets                        8.1.5
isoduration                       20.11.0
jedi                              0.19.2
Jinja2                            3.1.4
jiter                             0.5.0
json5                             0.10.0
jsonpointer                       3.0.0
jsonschema                        4.23.0
jsonschema-specifications         2023.12.1
jupyter                           1.1.1
jupyter_client                    8.6.3
jupyter-console                   6.6.3
jupyter_core                      5.7.2
jupyter-events                    0.10.0
jupyter-lsp                       2.2.5
jupyter_server                    2.14.2
jupyter_server_terminals          0.5.3
jupyterlab                        4.3.2
jupyterlab_pygments               0.3.0
jupyterlab_server                 2.27.3
jupyterlab_widgets                3.0.13
lark                              1.2.2
llvmlite                          0.43.0
lm-format-enforcer                0.10.6
MarkupSafe                        2.1.5
matplotlib-inline                 0.1.7
mistral_common                    1.4.3
mistune                           3.0.2
mpmath                            1.3.0
msgpack                           1.1.0
msgspec                           0.18.6
multidict                         6.1.0
multiprocess                      0.70.16
nbclient                          0.10.1
nbconvert                         7.16.4
nbformat                          5.10.4
nest-asyncio                      1.6.0
networkx                          3.3
notebook                          7.3.1
notebook_shim                     0.2.4
numba                             0.60.0
numpy                             1.26.4
nvidia-cublas-cu12                12.1.3.1
nvidia-cuda-cupti-cu12            12.1.105
nvidia-cuda-nvrtc-cu12            12.1.105
nvidia-cuda-runtime-cu12          12.1.105
nvidia-cudnn-cu12                 9.1.0.70
nvidia-cufft-cu12                 11.0.2.54
nvidia-curand-cu12                10.3.2.106
nvidia-cusolver-cu12              11.4.5.107
nvidia-cusparse-cu12              12.1.0.106
nvidia-ml-py                      12.560.30
nvidia-nccl-cu12                  2.20.5
nvidia-nvjitlink-cu12             12.6.68
nvidia-nvtx-cu12                  12.1.105
openai                            1.48.0
outlines                          0.0.46
overrides                         7.7.0
packaging                         24.1
pandas                            2.2.3
pandocfilters                     1.5.1
parso                             0.8.4
partial-json-parser               0.2.1.1.post4
pexpect                           4.9.0
pillow                            10.4.0
pip                               24.2
platformdirs                      4.3.6
plotly                            5.24.1
prometheus_client                 0.21.0
prometheus-fastapi-instrumentator 7.0.0
prompt_toolkit                    3.0.48
protobuf                          5.28.2
psutil                            6.0.0
ptyprocess                        0.7.0
pure_eval                         0.2.3
py-cpuinfo                        9.0.0
pyairports                        2.1.1
pyarrow                           17.0.0
pycountry                         24.6.1
pycparser                         2.22
pydantic                          2.9.2
pydantic_core                     2.23.4
Pygments                          2.18.0
python-dateutil                   2.9.0.post0
python-dotenv                     1.0.1
python-json-logger                2.0.7
pytz                              2024.2
PyYAML                            6.0.2
pyzmq                             26.2.0
ray                               2.37.0
referencing                       0.35.1
regex                             2024.9.11
requests                          2.32.3
rfc3339-validator                 0.1.4
rfc3986-validator                 0.1.1
rpds-py                           0.20.0
safetensors                       0.4.5
Send2Trash                        1.8.3
sentencepiece                     0.2.0
setuptools                        75.1.0
six                               1.16.0
sniffio                           1.3.1
soupsieve                         2.6
stack-data                        0.6.3
stanza                            1.9.2
starlette                         0.38.6
sympy                             1.13.3
tenacity                          9.0.0
terminado                         0.18.1
tiktoken                          0.7.0
timm                              1.0.12
tinycss2                          1.4.0
tokenizers                        0.20.0
tomli                             2.2.1
torch                             2.4.0
torchvision                       0.19.0
tornado                           6.4.2
tqdm                              4.66.5
traitlets                         5.14.3
transformers                      4.45.0
triton                            3.0.0
types-python-dateutil             2.9.0.20241003
typing_extensions                 4.12.2
tzdata                            2024.2
uri-template                      1.3.0
urllib3                           2.2.3
uvicorn                           0.30.6
uvloop                            0.20.0
vllm                              0.6.2
watchfiles                        0.24.0
wcwidth                           0.2.13
webcolors                         24.11.1
webencodings                      0.5.1
websocket-client                  1.8.0
websockets                        13.1
wheel                             0.44.0
widgetsnbextension                4.0.13
xformers                          0.0.27.post2
xxhash                            3.5.0
yarl                              1.12.1
zipp                              3.20.2

Currently Loaded Modules:
  1) eth_proxy   2) julia/1.10.3   3) gcc/12.2.0   4) stack/2024-06   5) r/4.3.2   6) hdf5/1.14.3   7) python/3.11.6   8) cuda/12.1.1   9) nccl/2.18.3-1  10) openblas/0.3.24  11) python_cuda/3.11.6

 

Testing Slurm Variables...
SLURM_JOB_USER=gcardenal
SLURM_TASKS_PER_NODE=1
SLURM_JOB_UID=608619
SLURM_TASK_PID=1647076
SLURM_JOB_GPUS=0,5
SLURM_LOCALID=0
SLURM_SUBMIT_DIR=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
SLURMD_NODENAME=eu-a65-07
SLURM_JOB_START_TIME=1737035774
SLURM_CLUSTER_NAME=euler-24-production
SLURM_JOB_END_TIME=1737050174
SLURM_CPUS_ON_NODE=8
SLURM_JOB_CPUS_PER_NODE=8
SLURM_GPUS_ON_NODE=2
SLURM_GTIDS=0
SLURM_JOB_PARTITION=gpupr.4h
SLURM_TRES_PER_TASK=cpu=8
SLURM_JOB_NUM_NODES=1
SLURM_JOBID=20959321
SLURM_GPUS=nvidia_a100_80gb_pcie:2
SLURM_JOB_QOS=es_ilic/gpupr/4
SLURM_PROCID=0
SLURM_CPUS_PER_TASK=8
SLURM_NTASKS=1
SLURM_TOPOLOGY_ADDR=.euler_a100_80_lca_ib.eu-a65-07
SLURM_TOPOLOGY_ADDR_PATTERN=switch.switch.node
SLURM_MEM_PER_CPU=10240
SLURM_SCRIPT_CONTEXT=prolog_task
SLURM_NODELIST=eu-a65-07
SLURM_JOB_ACCOUNT=gpupr/es_ilic
SLURM_PRIO_PROCESS=0
SLURM_NPROCS=1
SLURM_NNODES=1
SLURM_SUBMIT_HOST=eu-g9-021-4
SLURM_JOB_ID=20959321
SLURM_NODEID=0
SLURM_CONF=/cluster/slurm/adm/etc/slurm.conf
SLURM_JOB_NAME=llama_no_api
SLURM_JOB_GID=492010
SLURM_JOB_NODELIST=eu-a65-07
Thu Jan 16 14:56:27 2025       
+-----------------------------------------------------------------------------------------+
| NVIDIA-SMI 550.127.05             Driver Version: 550.127.05     CUDA Version: 12.4     |
|-----------------------------------------+------------------------+----------------------+
| GPU  Name                 Persistence-M | Bus-Id          Disp.A | Volatile Uncorr. ECC |
| Fan  Temp   Perf          Pwr:Usage/Cap |           Memory-Usage | GPU-Util  Compute M. |
|                                         |                        |               MIG M. |
|=========================================+========================+======================|
|   0  NVIDIA A100 80GB PCIe          On  |   00000000:07:00.0 Off |                    0 |
| N/A   35C    P0             43W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   1  NVIDIA A100 80GB PCIe          On  |   00000000:88:00.0 Off |                    0 |
| N/A   33C    P0             44W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
                                                                                         
+-----------------------------------------------------------------------------------------+
| Processes:                                                                              |
|  GPU   GI   CI        PID   Type   Process name                              GPU Memory |
|        ID   ID                                                               Usage      |
|=========================================================================================|
|  No running processes found                                                             |
+-----------------------------------------------------------------------------------------+
Node IP: 10.205.9.16
JobId=20959321 JobName=llama_no_api
   UserId=gcardenal(608619) GroupId=gcardenal-group(492010) MCS_label=N/A
   Priority=5810 Nice=0 Account=gpupr/es_ilic QOS=es_ilic/gpupr/4
   JobState=RUNNING Reason=None Dependency=(null)
   Requeue=0 Restarts=0 BatchFlag=1 Reboot=0 ExitCode=0:0
   RunTime=00:00:14 TimeLimit=04:00:00 TimeMin=N/A
   SubmitTime=2025-01-16T14:56:07 EligibleTime=2025-01-16T14:56:07
   AccrueTime=2025-01-16T14:56:07
   StartTime=2025-01-16T14:56:14 EndTime=2025-01-16T18:56:14 Deadline=N/A
   SuspendTime=None SecsPreSuspend=0 LastSchedEval=2025-01-16T14:56:14 Scheduler=Backfill
   Partition=gpupr.4h AllocNode:Sid=eu-g9-021-4:1978982
   ReqNodeList=(null) ExcNodeList=(null)
   NodeList=eu-a65-07
   BatchHost=eu-a65-07
   NumNodes=1 NumCPUs=8 NumTasks=1 CPUs/Task=8 ReqB:S:C:T=0:0:*:*
   ReqTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=85899345920
   AllocTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=0
   Socks/Node=* NtasksPerN:B:S:C=0:0:*:1 CoreSpec=*
   MinCPUsNode=8 MinMemoryCPU=10G MinTmpDiskNode=0
   Features=(null) DelayBoot=00:00:00
   OverSubscribe=OK Contiguous=0 Licenses=(null) Network=(null)
   Command=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/generate_answers.sh
   WorkDir=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
   StdErr=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api20959321.out
   StdIn=/dev/null
   StdOut=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api20959321.out
   TresPerJob=gres/gpu:nvidia_a100_80gb_pcie:2
   TresPerNode=gres/gpumem:80G
   TresPerTask=cpu=8
   

Running in standalone mode...
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] 
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] **************************************
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] Rendezvous info:
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] --rdzv-backend=c10d --rdzv-endpoint=localhost:0 --rdzv-id=8efc19dc-ddbc-4568-ab6b-3d3e4c2057e5
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] **************************************
I0116 14:56:30.510000 23063529457472 torch/distributed/run.py:859] 
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188] Starting elastic_operator with launch configs:
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   entrypoint       : get_model_answers_and_prompt_generation.py
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   min_nodes        : 1
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   max_nodes        : 1
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   nproc_per_node   : 1
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   run_id           : 8efc19dc-ddbc-4568-ab6b-3d3e4c2057e5
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   rdzv_backend     : c10d
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   rdzv_endpoint    : localhost:0
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   rdzv_configs     : {'timeout': 900}
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   max_restarts     : 0
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   monitor_interval : 5
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   log_dir          : /scratch/tmp.20959321.gcardenal/torchelastic_cz6wejpt
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188]   metrics_cfg      : {}
I0116 14:56:30.511000 23063529457472 torch/distributed/launcher/api.py:188] 
I0116 14:56:30.515000 23063529457472 torch/distributed/elastic/agent/server/api.py:866] [default] starting workers for entrypoint: python3
I0116 14:56:30.515000 23063529457472 torch/distributed/elastic/agent/server/api.py:699] [default] Rendezvous'ing worker group
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568] [default] Rendezvous complete for workers. Result:
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   restart_count=0
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   master_addr=eu-a65-07.euler.ethz.ch
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   master_port=34703
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   group_rank=0
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   group_world_size=1
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   local_ranks=[0]
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   role_ranks=[0]
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   global_ranks=[0]
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   role_world_sizes=[1]
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568]   global_world_sizes=[1]
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:568] 
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/api.py:707] [default] Starting worker group
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/agent/server/local_elastic_agent.py:168] Environment variable 'TORCHELASTIC_ENABLE_FILE_TIMER' not found. Do not start FileTimerServer.
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/multiprocessing/api.py:263] log directory set to: /scratch/tmp.20959321.gcardenal/torchelastic_cz6wejpt/8efc19dc-ddbc-4568-ab6b-3d3e4c2057e5__ehsg_i1
I0116 14:56:30.586000 23063529457472 torch/distributed/elastic/multiprocessing/api.py:358] Setting worker0 reply file to: /scratch/tmp.20959321.gcardenal/torchelastic_cz6wejpt/8efc19dc-ddbc-4568-ab6b-3d3e4c2057e5__ehsg_i1/attempt_0/0/error.json
2025-01-16 14:56:38.240235: E external/local_xla/xla/stream_executor/cuda/cuda_dnn.cc:9261] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered
2025-01-16 14:56:38.240282: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:607] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered
2025-01-16 14:56:38.241642: E external/local_xla/xla/stream_executor/cuda/cuda_blas.cc:1515] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered
2025-01-16 14:56:38.247175: I tensorflow/core/platform/cpu_feature_guard.cc:182] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.
To enable the following instructions: AVX2 FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.
2025-01-16 14:56:39.564973: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT
API call for Llama failed with error: Connection error.
Falling back to local Llama inference - Loading model...
Loading checkpoint shards:   0%|                                                                                                                                                                             | 0/30 [00:00<?, ?it/s]Loading checkpoint shards:   3%|█████▌                                                                                                                                                               | 1/30 [00:39<18:53, 39.09s/it]Loading checkpoint shards:   7%|███████████                                                                                                                                                          | 2/30 [01:47<26:16, 56.31s/it]Loading checkpoint shards:  10%|████████████████▌                                                                                                                                                    | 3/30 [02:15<19:34, 43.50s/it]Loading checkpoint shards:  13%|██████████████████████                                                                                                                                               | 4/30 [02:25<13:06, 30.24s/it]Loading checkpoint shards:  17%|███████████████████████████▌                                                                                                                                         | 5/30 [03:31<18:00, 43.21s/it]Loading checkpoint shards:  20%|█████████████████████████████████                                                                                                                                    | 6/30 [03:47<13:35, 33.99s/it]Loading checkpoint shards:  23%|██████████████████████████████████████▌                                                                                                                              | 7/30 [03:53<09:26, 24.62s/it]Loading checkpoint shards:  27%|████████████████████████████████████████████                                                                                                                         | 8/30 [03:58<06:48, 18.59s/it]Loading checkpoint shards:  30%|█████████████████████████████████████████████████▌                                                                                                                   | 9/30 [04:03<04:58, 14.20s/it]Loading checkpoint shards:  33%|██████████████████████████████████████████████████████▋                                                                                                             | 10/30 [04:08<03:48, 11.43s/it]Loading checkpoint shards:  37%|████████████████████████████████████████████████████████████▏                                                                                                       | 11/30 [05:09<08:24, 26.55s/it]Loading checkpoint shards:  40%|█████████████████████████████████████████████████████████████████▌                                                                                                  | 12/30 [05:13<05:56, 19.81s/it]Loading checkpoint shards:  43%|███████████████████████████████████████████████████████████████████████                                                                                             | 13/30 [06:52<12:23, 43.71s/it]Loading checkpoint shards:  47%|████████████████████████████████████████████████████████████████████████████▌                                                                                       | 14/30 [07:13<09:49, 36.82s/it]Loading checkpoint shards:  50%|██████████████████████████████████████████████████████████████████████████████████                                                                                  | 15/30 [07:49<09:10, 36.69s/it]Loading checkpoint shards:  53%|███████████████████████████████████████████████████████████████████████████████████████▍                                                                            | 16/30 [08:03<06:55, 29.68s/it]Loading checkpoint shards:  57%|████████████████████████████████████████████████████████████████████████████████████████████▉                                                                       | 17/30 [08:11<05:01, 23.20s/it]Loading checkpoint shards:  60%|██████████████████████████████████████████████████████████████████████████████████████████████████▍                                                                 | 18/30 [09:12<06:54, 34.51s/it]Loading checkpoint shards:  63%|███████████████████████████████████████████████████████████████████████████████████████████████████████▊                                                            | 19/30 [09:21<04:55, 26.88s/it]Loading checkpoint shards:  67%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████▎                                                      | 20/30 [09:27<03:26, 20.64s/it]Loading checkpoint shards:  70%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████▊                                                 | 21/30 [09:31<02:20, 15.66s/it]Loading checkpoint shards:  73%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▎                                           | 22/30 [09:44<01:58, 14.77s/it]Loading checkpoint shards:  77%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▋                                      | 23/30 [10:26<02:41, 23.10s/it]Loading checkpoint shards:  80%|███████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▏                                | 24/30 [10:31<01:45, 17.56s/it]Loading checkpoint shards:  83%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▋                           | 25/30 [11:02<01:48, 21.73s/it]Loading checkpoint shards:  87%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▏                     | 26/30 [11:18<01:19, 19.85s/it]Loading checkpoint shards:  90%|███████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▌                | 27/30 [11:21<00:44, 14.88s/it]Loading checkpoint shards:  93%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████           | 28/30 [11:25<00:23, 11.69s/it]Loading checkpoint shards:  97%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▌     | 29/30 [11:40<00:12, 12.64s/it]Loading checkpoint shards: 100%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 30/30 [11:42<00:00,  9.37s/it]Loading checkpoint shards: 100%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 30/30 [11:42<00:00, 23.41s/it]
Starting inference for question locally (Llama): How is HIV diagnosed?
HIV (Human Immunodeficiency Virus) diagnosis typically involves a combination of medical history, physical examination, and laboratory tests. Here's an overview of the diagnostic process:

1. **Medical History and Risk Assessment**: A healthcare provider will ask questions about your medical history, including any symptoms, previous illnesses, and risk factors for HIV, such as:
	* Unprotected sex with multiple partners
	* Injecting drugs or sharing needles
	* Having a sexually transmitted infection (STI)
	* Having a blood transfusion or organ transplant before 1985
	* Having a partner with HIV
2. **Physical Examination**: A healthcare provider will perform a physical examination to look for signs of HIV infection, such as:
	* Swollen lymph nodes
	* Skin rashes or lesions
	* Oral thrush (a fungal infection)
	* Weight loss or fatigue
3. **Laboratory Tests**: The following laboratory tests are used to diagnose HIV:
	* **Rapid Tests**: These tests detect the presence of HIV antibodies in blood, oral fluid, or urine. Results are available in 20-30 minutes.
	* **Enzyme-Linked Immunosorbent Assay (ELISA)**: This test detects HIV antibodies in blood and is often used as a follow-up to a rapid test.
	* **Western Blot**: This test is used to confirm the diagnosis of HIV and detect the presence of HIV antibodies.
	* **Polymerase Chain Reaction (PCR)**: This test detects the genetic material of the virus and is often used to diagnose HIV in infants or to monitor the viral load in people with HIV.
	* **Viral Load Test**: This test measures the amount of HIV in the blood and is used to monitor the effectiveness of treatment.
4. **Window Period**: The window period is the time between exposure to HIV and when the virus can be detected by a test. The window period varies depending on the type of test used:
	* Rapid tests: 23-90 days
	* ELISA: 23-90 days
	* Western Blot: 28-90 days
	* PCR: 10-33 days
5. **Confirmatory Testing**: If a test result is positive, a confirmatory test is performed to rule out false positives.
6. **Counseling and Follow-up**: If the diagnosis is confirmed, the healthcare provider will provide counseling and guidance on treatment options, prevention, and management of HIV.

It's essential to note that HIV testing is voluntary and confidential. If you think you may have been exposed to HIV, it's crucial to get tested and seek medical attention as soon as possible. Early diagnosis and treatment can significantly improve the chances of living a long and healthy life with HIV.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the different stages of HIV?
HIV (Human Immunodeficiency Virus) infection progresses through several stages, which can vary in duration and severity from person to person. The stages of HIV infection are:

**Stage 1: Acute HIV Infection (0-6 weeks)**

* This is the initial stage of HIV infection, where the virus replicates rapidly and the immune system responds to the infection.
* Symptoms may include flu-like illness, fever, rash, sore throat, and swollen lymph nodes.
* During this stage, the virus is highly contagious, and the individual may not know they are infected.

**Stage 2: Clinical Latency (6 weeks to 10-15 years)**

* Also known as the asymptomatic stage, where the virus is still active, but the immune system is able to keep it under control.
* The individual may not exhibit any symptoms, and the virus may not be detectable through standard tests.
* However, the virus is still present and can be transmitted to others.

**Stage 3: Symptomatic HIV Infection (10-15 years or more)**

* At this stage, the virus has weakened the immune system, and the individual may start to experience symptoms such as:
	+ Weight loss
	+ Fatigue
	+ Swollen lymph nodes
	+ Diarrhea
	+ Skin rashes
	+ Oral thrush
	+ Shingles
* The individual may also be more susceptible to opportunistic infections (OIs) such as tuberculosis, pneumonia, and toxoplasmosis.

**Stage 4: AIDS (Acquired Immune Deficiency Syndrome)**

* This is the most advanced stage of HIV infection, where the immune system is severely damaged, and the individual is highly susceptible to OIs and certain types of cancer.
* AIDS is defined by the presence of one or more OIs, such as:
	+ Pneumocystis pneumonia (PCP)
	+ Kaposi's sarcoma
	+ Non-Hodgkin lymphoma
	+ Toxoplasmosis
* Without treatment, AIDS can lead to severe illness and death.

**Undetectable Viral Load**

* With effective antiretroviral therapy (ART), it is possible to suppress the virus to undetectable levels, which significantly reduces the risk of transmission and slows disease progression.
* An undetectable viral load does not mean the individual is cured, but rather that the virus is under control, and the immune system is able to function normally.

It's essential to note that with proper treatment and care, individuals with HIV can live long and healthy lives, and the risk of transmission can be significantly reduced. If you have any concerns or questions, consult a healthcare professional for personalized advice.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV transmitted?
HIV (Human Immunodeficiency Virus) is transmitted through certain bodily fluids from a person who is infected with the virus. The main ways HIV is transmitted are:

1. **Unprotected sex**: HIV can be transmitted through vaginal, anal, or oral sex without using a condom or other barrier method. The virus can enter the body through the mucous membranes or open sores.
2. **Sharing needles or syringes**: Sharing needles or syringes with someone who is infected with HIV can transmit the virus through blood-to-blood contact.
3. **Mother-to-child transmission**: HIV can be transmitted from an infected mother to her child during pregnancy, childbirth, or breastfeeding.
4. **Blood transfusions**: In rare cases, HIV can be transmitted through blood transfusions if the blood is not properly screened for the virus.
5. **Occupational exposure**: Healthcare workers or others who come into contact with infected blood or bodily fluids may be at risk of transmission through needle sticks or other accidents.

The following bodily fluids can transmit HIV:

* Blood
* Semen
* Pre-seminal fluid (pre-cum)
* Vaginal fluids
* Breast milk
* Rectal fluids

It's essential to note that HIV is not transmitted through:

* Casual contact, such as hugging, shaking hands, or sharing food and drinks
* Air or water
* Mosquitoes or other insects
* Saliva, sweat, or tears, unless they contain blood
* Feces, unless they contain blood

To prevent HIV transmission, it's crucial to:

* Use condoms or other barrier methods during sex
* Get tested for HIV regularly
* Avoid sharing needles or syringes
* Use sterile equipment for injecting drugs
* Follow safe sex practices, such as using dental dams or condoms for oral sex
* Consider pre-exposure prophylaxis (PrEP) if you're at high risk of infection

If you're concerned about HIV transmission or have questions, consult a healthcare professional or a trusted resource, such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What comorbidities are common among people living 
People living with HIV (PLWH) are at increased risk of developing various comorbidities, which are health conditions that occur simultaneously with HIV infection. Some common comorbidities among PLWH include:

1. **Mental health disorders**: Depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders are prevalent among PLWH.
2. **Cardiovascular disease**: HIV infection increases the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.
3. **Chronic kidney disease**: HIV-related kidney disease, such as HIV-associated nephropathy (HIVAN), is a significant concern, particularly among African Americans.
4. **Liver disease**: Coinfection with hepatitis B or C viruses, as well as antiretroviral therapy (ART)-related liver toxicity, can lead to liver disease.
5. **Cancer**: PLWH are at higher risk of developing certain cancers, such as:
	* Kaposi's sarcoma
	* Non-Hodgkin lymphoma
	* Anal cancer
	* Cervical cancer
	* Lung cancer
6. **Osteoporosis**: HIV infection and ART can increase the risk of osteoporosis, particularly in older adults.
7. **Diabetes**: PLWH are more likely to develop insulin resistance and type 2 diabetes, which can be exacerbated by ART.
8. **Hypertension**: High blood pressure is common among PLWH, particularly those with kidney disease or cardiovascular disease.
9. **Chronic obstructive pulmonary disease (COPD)**: Smoking and HIV infection increase the risk of COPD.
10. **Neurological disorders**: HIV-associated neurocognitive disorders (HAND), such as dementia, and peripheral neuropathy are common comorbidities.
11. **Gastrointestinal disorders**: PLWH may experience gastrointestinal symptoms, such as diarrhea, nausea, and vomiting, due to HIV infection or ART side effects.
12. **Endocrine disorders**: Hypogonadism, adrenal insufficiency, and thyroid dysfunction can occur in PLWH.
13. **Sleep disorders**: Sleep apnea, insomnia, and restless leg syndrome are common among PLWH.
14. **Malnutrition and wasting**: Poor nutrition and weight loss can occur in PLWH, particularly in those with advanced disease or gastrointestinal symptoms.
15. **Dental problems**: PLWH are at higher risk of oral health issues, such as periodontal disease, tooth loss, and oral candidiasis.

It's essential for healthcare providers to screen for and manage these comorbidities to improve the overall health and well-being of PLWH. Regular monitoring, prevention, and treatment of comorbidities can help reduce the risk of complications and improve quality of life.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can HIV be prevented?
HIV (Human Immunodeficiency Virus) can be prevented through a combination of methods, including:

1. **Safe sex practices**: Using condoms consistently and correctly during vaginal, anal, and oral sex can significantly reduce the risk of HIV transmission.
2. **Pre-exposure prophylaxis (PrEP)**: Taking antiretroviral medication daily can prevent HIV infection in people who are at high risk of exposure.
3. **Post-exposure prophylaxis (PEP)**: Taking antiretroviral medication within 72 hours of potential exposure can prevent HIV infection.
4. **HIV testing and diagnosis**: Knowing one's HIV status and receiving early treatment can prevent transmission to others.
5. **Avoiding sharing needles and syringes**: Sharing needles and syringes can spread HIV, so it's essential to use clean equipment and avoid sharing.
6. **Using sterile equipment for tattooing and piercing**: Ensuring that tattoo and piercing equipment is sterile can prevent the transmission of HIV.
7. **Avoiding unprotected sex with multiple partners**: Reducing the number of sexual partners and using condoms consistently can lower the risk of HIV transmission.
8. **Getting vaccinated against other STIs**: Vaccines are available for some STIs, such as HPV and hepatitis B, which can also reduce the risk of HIV transmission.
9. **Using condoms with lubricant**: Using condoms with lubricant can reduce the risk of condom breakage and HIV transmission.
10. **Participating in HIV prevention programs**: Many communities offer HIV prevention programs, such as counseling, testing, and education, which can help individuals reduce their risk of HIV transmission.

Additionally, the following methods are being researched and developed:

1. **HIV vaccines**: Researchers are working on developing an HIV vaccine, which could provide long-term protection against the virus.
2. **Microbicides**: Microbicides are products that can be applied to the vagina or rectum to prevent HIV transmission.
3. **Treatment as prevention (TasP)**: Providing antiretroviral therapy to people living with HIV can reduce the risk of transmission to others.

It's essential to note that while these methods can reduce the risk of HIV transmission, they are not 100% effective. A combination of methods and a comprehensive approach to HIV prevention is the most effective way to reduce the risk of transmission.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How frequently ART must be taken?
Antiretroviral therapy (ART) is typically taken daily, and the frequency of taking the medication can vary depending on the specific regimen and the individual's treatment plan.

Most ART regimens involve taking a combination of medications, usually 1-3 times a day, with or without food. The exact frequency and timing of taking ART medications can vary, but common schedules include:

* Once daily: Taking all medications at the same time, usually in the morning or evening.
* Twice daily: Taking medications in the morning and evening, usually 12 hours apart.
* Three times daily: Taking medications in the morning, afternoon, and evening, usually 8 hours apart.

It's essential to take ART medications as directed by a healthcare provider, without missing doses or skipping days, to:

1. Maintain viral suppression: Keeping the virus at undetectable levels.
2. Prevent drug resistance: Reducing the risk of developing resistance to the medications.
3. Maintain immune function: Preserving the immune system's ability to fight off infections.

Adhering to the prescribed ART regimen is crucial for effective treatment and preventing the progression of HIV to AIDS. If you have any questions or concerns about your ART regimen, consult your healthcare provider for guidance.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can we prevent Perinatal transmission of HIV?
Preventing perinatal transmission of HIV (also known as mother-to-child transmission) is crucial to reduce the risk of HIV infection in newborns. Here are the ways to prevent perinatal transmission of HIV:

1. **HIV testing and counseling**: All pregnant women should be tested for HIV as part of routine prenatal care. If a woman is found to be HIV-positive, she should receive counseling and support to reduce the risk of transmission to her baby.
2. **Antiretroviral therapy (ART)**: HIV-positive pregnant women should start ART as soon as possible to reduce the viral load and prevent transmission to the baby. ART should be continued during pregnancy, childbirth, and after delivery.
3. **Combination antiretroviral therapy**: Using a combination of antiretroviral medications can reduce the risk of transmission to less than 1%.
4. **Elective cesarean delivery**: For women with high viral loads (above 1000 copies/mL) near the time of delivery, elective cesarean delivery can reduce the risk of transmission.
5. **Avoid breastfeeding**: HIV-positive mothers should not breastfeed their babies, as HIV can be transmitted through breast milk. Formula feeding or expressed breast milk from an HIV-negative donor can be used instead.
6. **Post-exposure prophylaxis (PEP)**: Newborns born to HIV-positive mothers should receive PEP, which involves administering antiretroviral medications to the baby within the first 6-12 hours of life.
7. **Pre-exposure prophylaxis (PrEP)**: For HIV-negative pregnant women who are at high risk of acquiring HIV, PrEP can be considered to reduce the risk of infection.
8. **Safe delivery practices**: Healthcare providers should follow safe delivery practices, such as using gloves and other protective equipment, to reduce the risk of transmission during delivery.
9. **HIV testing for newborns**: Newborns born to HIV-positive mothers should be tested for HIV at birth, 1-2 months, and 4-6 months of age to confirm the diagnosis.
10. **Family planning and reproductive health services**: HIV-positive women should have access to family planning and reproductive health services to prevent unintended pregnancies and reduce the risk of transmission.
11. **Male partner involvement**: Involving male partners in HIV testing, counseling, and treatment can help reduce the risk of transmission and promote a supportive environment for the HIV-positive mother.
12. **Follow-up care**: HIV-positive mothers and their babies should receive regular follow-up care, including HIV testing, ART, and other supportive services, to ensure the best possible outcomes.

By implementing these strategies, the risk of perinatal transmission of HIV can be significantly reduced, and the health and well-being of both mothers and babies can be protected.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the main cell types infected with HIV?
The main cell types infected with HIV (Human Immunodeficiency Virus) are:

1. **CD4+ T cells** (also known as T helper cells): These cells play a crucial role in the immune system, helping to coordinate the response to infections. HIV infects and destroys CD4+ T cells, which can lead to a weakened immune system.
2. **Macrophages**: These cells are a type of white blood cell that engulfs and digests foreign particles, bacteria, and dead cells. Macrophages can become infected with HIV and serve as a reservoir for the virus.
3. **Dendritic cells**: These cells are responsible for presenting antigens to T cells, helping to trigger an immune response. Dendritic cells can also become infected with HIV, which can facilitate the spread of the virus to other cells.

These cell types are the primary targets of HIV infection, and the virus uses various mechanisms to enter and replicate within them. The infection of these cells can lead to a range of immune system dysfunctions, including:

* Depletion of CD4+ T cells, which can impair the immune system's ability to respond to infections
* Activation of immune cells, which can lead to chronic inflammation and tissue damage
* Disruption of normal immune function, making it harder for the body to fight off opportunistic infections and diseases.

Understanding the cell types infected with HIV is essential for developing effective treatments and prevention strategies against the virus.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is the difference between HIV and AIDS?
HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are two related but distinct conditions.

**HIV:**

HIV is a virus that attacks the body's immune system, specifically the CD4 cells (also known as T cells), which help the immune system fight off infections. When HIV infects a person, it weakens their immune system, making them more susceptible to illnesses and infections. HIV is a chronic and manageable condition, and with proper treatment, people with HIV can live long and healthy lives.

**AIDS:**

AIDS, on the other hand, is a syndrome (a set of symptoms) that occurs when the HIV virus has severely damaged the immune system. AIDS is the most advanced stage of HIV infection, and it is characterized by a severely weakened immune system, making the person highly susceptible to opportunistic infections and certain types of cancer.

The key differences between HIV and AIDS are:

1. **Severity:** HIV is a viral infection, while AIDS is a syndrome that occurs when the HIV virus has caused significant damage to the immune system.
2. **Immune system damage:** HIV damages the immune system, while AIDS is characterized by a severely weakened immune system.
3. **Symptoms:** HIV may not cause symptoms for years, while AIDS is characterized by a range of symptoms, including weight loss, diarrhea, fever, and opportunistic infections.
4. **Treatment:** HIV can be managed with antiretroviral therapy (ART), while AIDS requires more aggressive treatment, including ART and treatment for opportunistic infections.

To summarize:

* HIV is a viral infection that can be managed with treatment.
* AIDS is a syndrome that occurs when the HIV virus has severely damaged the immune system, making the person highly susceptible to illnesses and infections.

It's worth noting that with proper treatment and care, people with HIV can prevent the progression to AIDS, and those with AIDS can manage their condition and improve their quality of life.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV not transmitted?
HIV (Human Immunodeficiency Virus) is not transmitted through the following ways:

1. **Casual contact**: Shaking hands, hugging, or touching someone with HIV does not transmit the virus.
2. **Air or water**: HIV is not spread through the air or water, so you cannot get it from breathing the same air as someone with HIV or drinking from the same water source.
3. **Insect bites**: Mosquitoes, ticks, and other insects do not transmit HIV.
4. **Food or drink**: You cannot get HIV from eating food or drinking beverages that have come into contact with someone who has HIV.
5. **Toilet seats or handles**: HIV is not spread through contact with toilet seats, handles, or other surfaces that may have come into contact with someone who has HIV.
6. **Sweat or tears**: HIV is not transmitted through sweat or tears, unless they are mixed with blood or other bodily fluids that contain the virus.
7. **Saliva**: HIV is not transmitted through saliva, unless it is mixed with blood or other bodily fluids that contain the virus.
8. **Coughing or sneezing**: HIV is not spread through coughing or sneezing, unless the person with HIV has a bleeding mouth or nose and the virus is present in their blood.
9. **Sharing food or utensils**: You cannot get HIV from sharing food or utensils with someone who has HIV.
10. **Touching or handling objects**: HIV is not transmitted through touching or handling objects that may have come into contact with someone who has HIV, such as doorknobs, light switches, or keyboards.

It's essential to remember that HIV is primarily transmitted through:

* Unprotected sex with someone who has HIV
* Sharing needles or syringes with someone who has HIV
* Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
* Blood transfusions from an infected donor (although this is extremely rare in countries with strict blood screening protocols)

If you have any concerns about HIV transmission or would like to know more about prevention and testing, consult a healthcare professional or a reputable resource, such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about the switch that occurs between
The switch from latent HIV infection to active infection is a complex process that involves multiple cellular and molecular mechanisms. Here's what is currently known about this switch:

**Latent HIV infection:**
Latent HIV infection refers to a state where the virus is present in the body, but it is not actively replicating. During latency, the virus integrates into the host genome and remains dormant, often in memory CD4+ T cells. This latent reservoir is thought to be the primary barrier to curing HIV.

**Reactivation of latent HIV:**
The reactivation of latent HIV is triggered by various factors, including:

1. **Cellular activation**: When latently infected cells are activated, either by antigen presentation or other stimuli, they can begin to express viral genes and produce new virus particles.
2. **Inflammation**: Inflammatory cytokines, such as TNF-α and IL-1β, can reactivate latent HIV by inducing the expression of viral genes.
3. **Epigenetic changes**: Epigenetic modifications, such as histone acetylation and DNA methylation, can influence the expression of viral genes and reactivate latent HIV.
4. **Viral proteins**: Some viral proteins, like Tat and Rev, can reactivate latent HIV by binding to specific DNA sequences and promoting viral transcription.

**Key players in the switch:**
Several cellular and molecular players are involved in the switch from latent to active HIV infection:

1. **NF-κB**: The transcription factor NF-κB plays a crucial role in the reactivation of latent HIV. It is activated by various stimuli, including inflammation and cellular activation, and induces the expression of viral genes.
2. **P-TEFb**: The positive transcription elongation factor b (P-TEFb) is a complex that phosphorylates and activates the viral transcription factor Tat, leading to the reactivation of latent HIV.
3. **HDACs**: Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, leading to chromatin compaction and suppression of viral gene expression. Inhibition of HDACs can reactivate latent HIV.
4. **MicroRNAs**: MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to messenger RNA (mRNA). Some miRNAs, such as miR-132, can reactivate latent HIV by targeting negative regulators of viral transcription.

**Consequences of the switch:**
The switch from latent to active HIV infection has significant consequences, including:

1. **Viral replication**: The reactivation of latent HIV leads to the production of new virus particles, which can infect other cells and contribute to the progression of HIV disease.
2. **Immune activation**: The reactivation of latent HIV can also lead to immune activation, which can exacerbate HIV-related inflammation and tissue damage.
3. **Antiretroviral therapy (ART) resistance**: The reactivation of latent HIV can lead to the emergence of ART-resistant viral strains, making treatment more challenging.

**Current research and therapeutic strategies:**
To better understand the switch from latent to active HIV infection, researchers are exploring various therapeutic strategies, including:

1. **Latency-reversing agents**: Compounds that can reactivate latent HIV, such as histone deacetylase inhibitors (HDACis) and protein kinase C (PKC) agonists, are being investigated as potential therapeutic agents.
2. **Immune-based therapies**: Therapies that target the immune system, such as checkpoint inhibitors and therapeutic vaccines, are being explored to enhance the elimination of latently infected cells.
3. **Gene editing**: Gene editing technologies, such as CRISPR/Cas9, are being investigated to selectively eliminate latently infected cells or disrupt viral genes.

Overall, the switch from latent to active HIV infection is a complex process that involves multiple cellular and molecular mechanisms. Understanding these mechanisms is crucial for the development of effective therapeutic strategies to cure HIV.
Saved Llama answers (category=1, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_1.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 58-year-old woman with HIV infection is brought 
Based on the clinical presentation, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).

Here's why:

1. **Clinical presentation**: The patient's symptoms, such as headaches, blurred vision, confusion, ataxia, and memory impairment, are consistent with a brain lesion.
2. **Immunocompromised state**: The patient's HIV infection and low CD4+ T-lymphocyte count (90/μL) indicate a compromised immune system, which increases the risk of opportunistic infections and malignancies, including PCNSL.
3. **Cerebrospinal fluid analysis**: The presence of lymphocytic predominant pleocytosis suggests a lymphoproliferative disorder.
4. **PCR positive for Epstein-Barr virus DNA**: EBV is a known risk factor for PCNSL, particularly in immunocompromised individuals.
5. **MRI findings**: The solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum is consistent with PCNSL. The lesion's location and appearance are typical for this type of tumor.

PCNSL is a rare and aggressive non-Hodgkin lymphoma that arises in the brain, spinal cord, or eyes. It is more common in immunocompromised individuals, such as those with HIV/AIDS. The presence of EBV DNA in the cerebrospinal fluid supports the diagnosis, as EBV is thought to play a role in the pathogenesis of PCNSL.

Other possible diagnoses, such as toxoplasmosis or progressive multifocal leukoencephalopathy (PML), are less likely given the combination of clinical, laboratory, and imaging findings. Toxoplasmosis typically presents with multiple ring-enhancing lesions, and PML usually shows a more diffuse, asymmetric white matter involvement without significant mass effect or enhancement.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 25-year-old sexually active male presents to an 
The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is Enfuvirtide (also known as T-20).

However, a more commonly used medication that targets the gp41 subunit is not Enfuvirtide, but rather a class of medications that are more frequently prescribed. This class of medications is known as HIV fusion inhibitors, but a more commonly prescribed class of medications that target the gp41 subunit is not available.

A more accurate answer would be that the class of medications that target the HIV envelope glycoprotein, specifically the gp41 subunit, is the HIV fusion inhibitors, with Enfuvirtide being an example. But Enfuvirtide is not commonly used due to its route of administration (subcutaneous injection) and the availability of other oral medications.

It's worth noting that Enfuvirtide is not the first-line treatment for HIV, and it's usually reserved for patients who have failed other treatments or have resistance to other medications.

A more commonly prescribed medication that targets the HIV envelope glycoprotein is not available, but medications that target other parts of the HIV life cycle, such as reverse transcriptase inhibitors, protease inhibitors, or integrase inhibitors, are commonly used in combination to treat HIV infection.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A mother with HIV has given birth to a healthy boy
If the mother boiled the formula longer than needed, the molecular process that could be impaired is the denaturation of proteins and the degradation of vitamins, particularly Vitamin C (ascorbic acid). However, the more specific process related to Vitamin C is its oxidation and degradation.

Vitamin C is a water-soluble vitamin that is sensitive to heat, water, and oxygen. When formula is boiled for an extended period, the Vitamin C molecules can undergo oxidation reactions, leading to the formation of inactive compounds such as 2,3-diketogulonic acid. This process is accelerated by heat, oxygen, and the presence of metals like copper and iron.

The oxidation reaction involves the loss of electrons from the Vitamin C molecule, resulting in the formation of a stable but inactive compound. This process can be represented by the following equation:

C₆H₈O₆ (Vitamin C) → C₆H₆O₆ (2,3-diketogulonic acid) + 2H+ + 2e-

The degradation of Vitamin C can be minimized by boiling the formula for the recommended time, using a thermometer to ensure the temperature does not exceed 100°C (212°F), and storing the formula in a cool, dry place.

In summary, the molecular process impaired by overheating the formula is the oxidation and degradation of Vitamin C, leading to the loss of its nutritional value and potential harm to the infant.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 35-year-old woman presents to a physician’s offi
Given the patient's diagnosis of acute pancreatitis following the initiation of combination anti-retroviral treatment (ART) including zidovudine, didanosine, and efavirenz for HIV, it's crucial to identify the potential culprit among her medications that could have contributed to the development of pancreatitis. Didanosine is well-known for its association with an increased risk of pancreatitis, a potentially life-threatening condition.

After the pancreatitis resolves with treatment, precautions in her medication regimen will be required to prevent recurrence. The primary precaution would be to **discontinue didanosine** due to its established link with pancreatitis. This medication will need to be replaced with an alternative antiretroviral drug that does not carry the same risk.

The revised ART regimen should be selected based on the patient's viral load, resistance testing (if available), and the side effect profile of the alternative medications. The goal is to maintain effective viral suppression while minimizing the risk of adverse effects, including pancreatitis.

**Zidovudine and efavirenz** can typically be continued if they are well-tolerated and effective, as they are not commonly associated with pancreatitis. However, the entire regimen should be reviewed, and adjustments made as necessary to ensure the best possible outcomes for the patient, balancing efficacy with safety.

Monitoring for signs of pancreatitis and other potential side effects of the new regimen will be important, along with regular follow-up appointments to assess the effectiveness of the treatment and the patient's overall health status.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A physician scientist is looking for a more effici
To determine the most likely target of the antibody, we need to consider the HIV envelope proteins that are typically targeted by the natural humoral immune response.

The HIV envelope is composed of two main proteins: gp120 and gp41. These proteins are embedded in the viral membrane and play a crucial role in the attachment and entry of the virus into host cells.

* gp120 is responsible for binding to the CD4 receptor on host cells, while
* gp41 is involved in the fusion of the viral and host cell membranes.

Both gp120 and gp41 are immunogenic and can elicit an antibody response. However, gp120 is generally more accessible to the immune system and is often the primary target of neutralizing antibodies.

Given this information, the most likely target of the antibody being designed by the physician scientist is **gp120**. This protein is a key component of the HIV envelope and is already targeted by the natural humoral immune response. A more potent antibody against gp120 could potentially provide improved neutralization of the virus and better protection against infection.

It's worth noting that gp41 is also a potential target, but gp120 is generally considered a more promising target for antibody-based therapies due to its role in viral attachment and entry.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 50-year-old HIV-positive male presents to the ER
Based on the clinical presentation and biopsy findings, the most likely causal organism is Aspergillus.

The key points that lead to this diagnosis are:

1. **Fibrocavitary lesion in the right middle lobe**: This type of lesion is commonly seen in chronic pulmonary aspergillosis, particularly in immunocompromised patients like those with HIV.
2. **Septate hyphae that branch at acute angles**: This is a characteristic microscopic feature of Aspergillus species. The hyphae are septate, meaning they have divisions or septa within the hypha, and they branch at acute angles (typically 45 degrees), which is a distinctive feature of Aspergillus.
3. **HIV-positive status**: Immunocompromised patients, including those with HIV, are more susceptible to opportunistic infections like aspergillosis.
4. **Symptoms of fever and hemoptysis**: These symptoms are consistent with an invasive pulmonary aspergillosis infection.

Aspergillus is a common cause of opportunistic infections in immunocompromised patients, and the combination of clinical and microscopic findings in this case makes it the most likely causal organism.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 43-year-old man with HIV infection comes to the 
The addition of valganciclovir to the patient's current medication regimen, which includes zidovudine, lamivudine, and dolutegravir, puts the patient at greatest risk for hematologic adverse effects, particularly **neutropenia** and **anemia**.

Valganciclovir is a cytomegalovirus (CMV) antiviral medication that can cause bone marrow suppression, leading to decreased production of blood cells, including neutrophils (neutropenia) and red blood cells (anemia). Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), is also known to cause bone marrow suppression, which can increase the risk of neutropenia and anemia when used in combination with valganciclovir.

The concomitant use of these two medications may exacerbate the risk of hematologic adverse effects, particularly in a patient with HIV infection who may already be at risk for bone marrow suppression due to the underlying disease or other medications.

Therefore, the patient should be closely monitored for signs and symptoms of neutropenia and anemia, such as fever, fatigue, and shortness of breath, and regular complete blood counts (CBCs) should be performed to assess the risk of these adverse effects.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 28-year-old G1P0 woman at 16 weeks estimated ges
For a newborn suspected of being exposed to HIV, the most appropriate diagnostic test is the HIV DNA polymerase chain reaction (PCR) test. This test directly detects the genetic material of the virus and can identify HIV infection in infants as young as a few weeks old.

The HIV DNA PCR test is preferred over other tests, such as the HIV antibody test, for several reasons:

1. **Early detection**: The HIV DNA PCR test can detect HIV infection in newborns much earlier than antibody tests. Antibodies to HIV, which are passed from mother to child, can remain positive in the infant for up to 18 months, even if the child is not infected. This makes it difficult to determine whether a positive antibody test in a newborn is due to maternal antibodies or actual infection.
2. **Accuracy**: The HIV DNA PCR test is highly sensitive and specific for detecting HIV infection in infants.
3. **Rapid results**: The test can provide results within a few days, allowing for prompt initiation of antiretroviral therapy if the infant is infected.

The American Academy of Pediatrics recommends that all infants born to HIV-positive mothers have an HIV DNA PCR test performed at 14-21 days of age, with repeat testing at 1-2 months and 4-6 months of age to confirm the diagnosis.

In this patient's case, the HIV DNA PCR test would be the most appropriate diagnostic test to address her concern about possible transmission of HIV to her baby, as it can provide an early and accurate diagnosis of HIV infection in the newborn.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 32-year-old man comes to the office for a routin
This is a complex and sensitive situation, requiring careful consideration of ethical, legal, and medical principles. The most appropriate next step by the physician would be to:

1. **Counsel the patient on the importance of disclosure**: The physician should explain to the patient the risks of not disclosing his HIV status to his wife, including the potential for transmission and the importance of her getting tested and receiving appropriate care.
2. **Emphasize the patient's responsibility to inform his partner**: The physician should stress that it is the patient's responsibility to inform his wife about his HIV status, as she may be at risk of infection.
3. **Offer support and resources for disclosure**: The physician can offer to provide the patient with resources and support to help him disclose his HIV status to his wife, such as counseling or educational materials.
4. **Respect patient confidentiality, but also consider public health reporting requirements**: The physician is bound by confidentiality laws, such as HIPAA, to protect the patient's personal health information. However, HIV is a reportable disease, and the physician may be required to report the patient's diagnosis to public health authorities. The physician should inform the patient about these reporting requirements.
5. **Not disclose the patient's diagnosis to his wife without his consent**: Unless there is a significant risk of harm to the wife or others, the physician should not disclose the patient's diagnosis to his wife without his consent. However, the physician may be able to encourage the patient to disclose his status to his wife or offer to facilitate a joint counseling session.

It's essential to note that the physician's primary responsibility is to the patient, and breaching confidentiality without consent could damage the patient-physician relationship and potentially harm the patient. However, the physician also has a duty to protect the public's health and prevent harm to others.

In this scenario, the physician should:

* Not disclose the patient's diagnosis to his wife without his consent.
* Encourage the patient to disclose his HIV status to his wife and offer support and resources to facilitate this process.
* Report the patient's HIV diagnosis to public health authorities, as required by law.
* Document the patient's diagnosis, counseling, and any discussions about disclosure in the medical record.

Ultimately, the physician should strive to balance the patient's right to confidentiality with the need to protect the public's health and prevent harm to others.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 41-year-old HIV-positive male presents to the ER
Based on the clinical presentation and laboratory findings, the most likely diagnosis is cryptococcal meningitis caused by Cryptococcus neoformans. The expected diagnostic test results would include:

1. **Positive Cryptococcal Antigen (CRAG) test**: This is a latex agglutination test that detects the presence of cryptococcal capsular antigen in the CSF or serum. It is a sensitive and specific test for diagnosing cryptococcal meningitis.
2. **Positive culture of CSF for Cryptococcus neoformans**: The CSF sample would be sent for fungal culture, which would grow Cryptococcus neoformans, confirming the diagnosis.
3. **Elevated CSF opening pressure**: Cryptococcal meningitis often causes increased intracranial pressure, which would be reflected in an elevated CSF opening pressure during the lumbar puncture.
4. **CSF pleocytosis with lymphocytic predominance**: Although not mentioned in the initial presentation, cryptococcal meningitis typically causes a lymphocytic pleocytosis in the CSF, with an increased number of white blood cells, predominantly lymphocytes.
5. **Imaging studies (e.g., MRI or CT) may show**: Hydrocephalus, cerebral edema, or cryptococcomas (fungal abscesses) in the brain, although these findings are not universal and may not be present in all cases.

The India ink staining of the CSF, which reveals encapsulated yeast with narrow-based buds, is a classic diagnostic feature of Cryptococcus neoformans. The decrease in CSF glucose and increase in CSF protein are also consistent with a fungal meningitis, such as cryptococcal meningitis.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama):  What would be the best methodological approach to
Studying microRNAs (miRNAs) as therapeutic targets in HIV patients requires a comprehensive and multi-disciplinary approach. Here's a suggested methodological framework:

**Research Design:**

1. **Literature Review**: Conduct a thorough review of existing literature on miRNAs, HIV, and their interactions to identify potential miRNA targets and their roles in HIV pathogenesis.
2. **Hypothesis Generation**: Based on the literature review, formulate hypotheses about the potential therapeutic targets and their mechanisms of action.
3. **Study Design**: Design a study that incorporates both in vitro and in vivo experiments to validate the hypotheses.

**In Vitro Experiments:**

1. **Cell Culture**: Use relevant cell lines (e.g., T cells, macrophages, dendritic cells) to study the effects of miRNAs on HIV replication and immune response.
2. **miRNA Overexpression/Knockdown**: Use techniques like transfection or lentiviral vectors to overexpress or knockdown specific miRNAs in cells.
3. **HIV Infection**: Infect cells with HIV and measure the effects of miRNA modulation on viral replication, immune response, and cell survival.
4. **High-Throughput Screening**: Use high-throughput screening techniques (e.g., microarrays, next-generation sequencing) to identify miRNAs that are differentially expressed in response to HIV infection.

**In Vivo Experiments:**

1. **Animal Models**: Use relevant animal models (e.g., humanized mice, non-human primates) to study the effects of miRNA modulation on HIV infection and disease progression.
2. **miRNA Delivery**: Use techniques like viral vectors, nanoparticles, or liposomes to deliver miRNAs to specific tissues or cells in vivo.
3. **HIV Infection**: Infect animals with HIV and measure the effects of miRNA modulation on viral load, immune response, and disease progression.

**Bioinformatics and Computational Analysis:**

1. **miRNA Target Prediction**: Use bioinformatics tools (e.g., TargetScan, miRBase) to predict the targets of miRNAs and their potential roles in HIV pathogenesis.
2. **Network Analysis**: Use network analysis tools (e.g., Cytoscape, STRING) to study the interactions between miRNAs, their targets, and other molecules involved in HIV infection.
3. **Machine Learning**: Use machine learning algorithms (e.g., random forest, support vector machines) to identify patterns and correlations between miRNA expression, HIV infection, and disease progression.

**Clinical Samples and Patient Data:**

1. **Patient Recruitment**: Recruit HIV patients and collect clinical samples (e.g., blood, tissue biopsies) to study the expression of miRNAs and their targets.
2. **miRNA Profiling**: Use techniques like microarrays or next-generation sequencing to profile miRNA expression in patient samples.
3. **Correlation Analysis**: Correlate miRNA expression with clinical parameters (e.g., viral load, CD4 count, disease progression) to identify potential biomarkers and therapeutic targets.

**Validation and Translation:**

1. **Validation**: Validate the findings from in vitro and in vivo experiments using clinical samples and patient data.
2. **Therapeutic Development**: Develop and test miRNA-based therapeutics (e.g., miRNA mimics, inhibitors) in preclinical models and clinical trials.
3. **Biomarker Development**: Develop and validate miRNA-based biomarkers for diagnosis, prognosis, and monitoring of HIV infection and disease progression.

By following this methodological framework, researchers can comprehensively study miRNAs as therapeutic targets in HIV patients and develop effective miRNA-based treatments for HIV infection.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about DNA methylation profiles in pa
DNA methylation profiles have been extensively studied in patients with latent HIV-1 or active infection, revealing significant changes in the epigenetic landscape. Here's a summary of the current knowledge:

**Latent HIV-1:**

1. **Hypomethylation of HIV-1 promoter**: In latent HIV-1 infection, the promoter region of the virus is often hypomethylated, which allows for the maintenance of latency. Hypomethylation is associated with the recruitment of repressive chromatin complexes, such as histone deacetylases (HDACs) and polycomb repressive complexes (PRCs).
2. **Methylation of host genes**: Latent HIV-1 infection is also associated with changes in the methylation status of host genes involved in immune response, cell cycle regulation, and apoptosis. For example, genes involved in the interferon response, such as IFITM1 and IFITM3, are often hypermethylated, leading to their downregulation.
3. **Epigenetic silencing of viral genes**: In latent HIV-1 infection, viral genes are epigenetically silenced through the action of repressive chromatin complexes and DNA methylation. This silencing is thought to contribute to the maintenance of latency.

**Active HIV-1 infection:**

1. **Hyperactivation of host genes**: Active HIV-1 infection is characterized by the hyperactivation of host genes involved in immune response, cell proliferation, and inflammation. This is often accompanied by the hypomethylation of these genes, allowing for their increased expression.
2. **Methylation of tumor suppressor genes**: Active HIV-1 infection has been linked to the methylation and silencing of tumor suppressor genes, such as p16INK4a and p21CIP1. This can contribute to the development of HIV-1-associated cancers, such as Kaposi's sarcoma and non-Hodgkin lymphoma.
3. **Epigenetic regulation of viral replication**: DNA methylation also plays a role in regulating viral replication during active HIV-1 infection. For example, the methylation status of the HIV-1 long terminal repeat (LTR) can influence viral transcription and replication.

**Commonalities between latent and active infection:**

1. **Global DNA hypomethylation**: Both latent and active HIV-1 infections are associated with global DNA hypomethylation, which can contribute to genomic instability and the development of HIV-1-associated diseases.
2. **Epigenetic dysregulation**: HIV-1 infection, regardless of its status, is characterized by epigenetic dysregulation, including changes in DNA methylation, histone modifications, and chromatin structure. This dysregulation can contribute to the pathogenesis of HIV-1 and the development of associated diseases.

**Therapeutic implications:**

1. **Epigenetic therapy**: Targeting epigenetic regulators, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), may offer a new approach to treating HIV-1 infection. Epigenetic therapy could potentially reactivate latent HIV-1, making it more susceptible to antiretroviral therapy (ART).
2. **Biomarkers for diagnosis and monitoring**: DNA methylation profiles could serve as biomarkers for diagnosing and monitoring HIV-1 infection, as well as for predicting disease progression and response to treatment.

In summary, DNA methylation profiles in patients with latent HIV-1 or active infection reveal significant changes in the epigenetic landscape, which can contribute to the pathogenesis of HIV-1 and the development of associated diseases. Further research is needed to fully understand the role of epigenetics in HIV-1 infection and to explore the therapeutic potential of targeting epigenetic regulators.
Saved Llama answers (category=3, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_3.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 26-year-old female with AIDS (CD4 count: 47) pre
Based on the patient's presentation and the results of the lumbar puncture, it is likely that she has cryptococcal meningitis, a common opportunistic infection in patients with AIDS. The treatment initiated by the emergency physician, IV amphotericin B and PO flucytosine, is appropriate for cryptococcal meningitis.

In the acute setting, an additional treatment that may be warranted is the administration of corticosteroids, such as dexamethasone or prednisone, to reduce the risk of immune reconstitution inflammatory syndrome (IRIS) and to manage increased intracranial pressure (ICP). However, the more critical additional treatment in this case would be to consider the management of elevated intracranial pressure.

The patient's opening pressure of 285 mm H2O is significantly elevated, indicating increased ICP. To manage this, the following treatments may be considered:

1. Frequent lumbar punctures to remove cerebrospinal fluid (CSF) and reduce ICP.
2. Acetazolamide, a carbonic anhydrase inhibitor, to decrease CSF production.
3. Mannitol or other hyperosmolar agents to reduce ICP.
4. Close monitoring of the patient's neurological status and consideration of repeat imaging or ICP monitoring if available.

It is essential to manage the elevated ICP to prevent further neurological deterioration and potential complications such as brain herniation. The patient should be closely monitored in an intensive care setting, and a neurologist or infectious disease specialist should be consulted to guide further management.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): You are reviewing raw data from a research study p
To calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we need to understand what NPV represents. The NPV is the probability that a person with a negative test result truly does not have the disease. It is calculated using the formula:

NPV = True Negatives / (True Negatives + False Negatives)

From the information provided:

- True Negatives (TN) are the patients without AIDS who tested negative. Since 5 out of 250 patients without AIDS tested positive, the number of patients without AIDS who tested negative is 250 - 5 = 245.
- False Negatives (FN) are the patients with AIDS who tested negative. Since 240 out of 250 patients with AIDS tested positive, the number of patients with AIDS who tested negative is 250 - 240 = 10.

Plugging these values into the NPV formula:

NPV = TN / (TN + FN) = 245 / (245 + 10) = 245 / 255

NPV ≈ 0.9608 or 96.08%

Therefore, the Negative Predictive Value of this novel test is approximately 96.08%, meaning that about 96.08% of the patients who test negative for AIDS using this screening examination truly do not have AIDS.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 46-year-old Caucasian male with past medical his
Given the patient's presentation of sudden weakness in one hand, particularly with a history of HIV and inconsistent adherence to antiretroviral therapy (ART), along with fever and a significant past medical history, the differential diagnosis is broad. However, the key findings here are the focal neurological deficit (3/5 strength in the distal muscles of the right extremity) and the fever, which suggest an infectious or inflammatory cause. In a patient with a low CD4 count, the risk of opportunistic infections (OIs) is high, and the presence of fever further raises the concern for an infectious process.

The next best step in management for this patient involves several concurrent actions:

1. **Stabilization and Supportive Care**: Ensure the patient is stable from a cardiovascular and respiratory standpoint. Given the fever, providing antipyretics (e.g., acetaminophen) and ensuring adequate hydration is important.

2. **Neuroimaging**: Given the focal neurological deficit, imaging of the brain is crucial to rule out conditions such as stroke, brain abscess, or progressive multifocal leukoencephalopathy (PML), which is an opportunistic infection seen in patients with low CD4 counts. A non-contrast CT scan of the head can be an initial step, but given the patient's HIV status and the nature of his symptoms, an MRI of the brain with and without contrast would be more informative, especially for diagnosing conditions like PML or toxoplasmosis.

3. **Laboratory Evaluation**: 
   - **Complete Blood Count (CBC)**: To evaluate for signs of infection or inflammation.
   - **Blood Cultures**: If there's suspicion of bacteremia or sepsis.
   - **HIV Viral Load**: To assess the effectiveness of the current ART regimen and consider potential resistance.
   - **CD4 Count**: Although the patient's CD4 count is known, monitoring it can help in assessing the immune status over time.
   - **Toxoplasma IgG**: Given the patient's immunocompromised state, testing for toxoplasmosis, which can cause focal neurological deficits, is reasonable.

4. **Infectious Disease Consultation**: Early consultation with an infectious disease specialist can help in guiding the diagnostic workup and management, especially considering the patient's HIV status and potential for opportunistic infections.

5. **Neurology Consultation**: A neurologist can provide valuable insight into the patient's neurological symptoms and help in interpreting neuroimaging findings.

6. **Adherence to ART**: It's crucial to address the patient's inconsistent adherence to his HIV medications. Improving adherence can significantly impact his immune status and reduce the risk of opportunistic infections.

7. **Empiric Treatment**: Depending on the suspected cause, empiric treatment may be initiated. For example, if toxoplasmosis is suspected, empiric treatment with sulfadiazine and pyrimethamine can be started while awaiting diagnostic confirmation.

In summary, the next best step involves a comprehensive approach including stabilization, neuroimaging, laboratory evaluation, specialist consultations, and consideration of empiric treatment based on likely diagnoses, all while addressing the patient's ART adherence.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 44-year-old man is brought to the emergency depa
The patient's clinical presentation, laboratory results, and imaging findings suggest a diagnosis of Progressive Multifocal Leukoencephalopathy (PML).

Here's a breakdown of the key points that support this diagnosis:

1. **Clinical presentation**: The patient has a 1-week history of right leg weakness, unsteady gait, and multiple falls, which suggests a neurological disorder. Additionally, he has become more forgetful, has difficulty with daily tasks, and has developed psychiatric symptoms such as paranoia, agitation, and restlessness.
2. **HIV status and immune suppression**: The patient has a low CD4+ count (56/μL) and a high HIV viral load (> 100,000 copies/mL), indicating severe immune suppression. This increases his risk for opportunistic infections, including PML.
3. **Neurological examination**: The patient has right lower extremity weakness with normal tone and no other focal deficits, which is consistent with a subcortical white matter lesion.
4. **Imaging findings**: The MRI shows disseminated, nonenhancing white matter lesions with no mass effect, which is characteristic of PML. The lesions are typically located in the subcortical white matter and do not enhance with contrast.
5. **Laboratory results**: The patient's laboratory results do not show evidence of other opportunistic infections, such as cryptococcal meningitis (negative cryptococcal antigen) or toxoplasmosis (positive Toxoplasma gondii IgG, but this is a common finding in HIV-infected individuals and does not necessarily indicate active infection).

PML is a rare and often fatal demyelinating disease caused by the JC virus, which is a common virus that typically does not cause symptoms in healthy individuals. However, in immunocompromised individuals, such as those with advanced HIV infection, the JC virus can reactivate and cause PML.

Other possible diagnoses, such as toxoplasmosis or primary central nervous system lymphoma, are less likely given the patient's clinical presentation, laboratory results, and imaging findings. However, a definitive diagnosis of PML would require a brain biopsy or detection of JC virus DNA in the cerebrospinal fluid.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 25-year-old nulliparous woman at 8 weeks' gestat
At the first prenatal visit, several tests and screenings are recommended to ensure the health and well-being of both the mother and the fetus. Given the information provided, here are the tests that should be considered for this 25-year-old nulliparous woman at 8 weeks' gestation:

1. **Confirmation of Pregnancy**: Although she is already aware of her pregnancy, a urine or blood pregnancy test can confirm the pregnancy if not already done.

2. **Complete Blood Count (CBC)**: To check for anemia and other blood disorders.

3. **Blood Type and Rh Factor**: Determining her blood type (A, B, AB, or O) and Rh factor (positive or negative) is crucial. If she is Rh-negative, she may need Rh immune globulin at certain points during her pregnancy to prevent sensitization.

4. **Rubella (German Measles) Immunity**: Checking for immunity to rubella is important to assess the risk of congenital rubella syndrome.

5. **Hepatitis B Surface Antigen (HBsAg)**: Screening for hepatitis B infection to identify those who can transmit the virus to their newborns.

6. **Syphilis Screening**: This is recommended for all pregnant women at the first prenatal visit.

7. **HIV Screening**: Although she tested negative 4 years ago, the CDC recommends HIV screening for all pregnant women at the first prenatal visit, regardless of previous test results, due to the potential for new exposures.

8. **Chlamydia trachomatis and Neisseria gonorrhoeae Screening**: The CDC recommends screening for these sexually transmitted infections (STIs) for all pregnant women under 25 years old at the first prenatal visit, as well as for those at increased risk. Since she is under 25, screening is recommended despite her previous negative tests.

9. **Urine Culture**: To screen for asymptomatic bacteriuria, which can increase the risk of pyelonephritis and other complications during pregnancy.

10. **Pap Smear**: If she is due for a routine Pap smear according to current guidelines (typically every 3 years for women aged 21-29 with a normal previous result), it may be performed. However, the primary focus at this visit is on pregnancy-related care.

11. **First Trimester Screening for Aneuploidy**: This includes non-invasive screening tests such as the combined test (which combines ultrasound measurement of nuchal translucency with serum markers) or cell-free DNA screening, typically offered between 11 and 14 weeks of gestation but can be discussed at the initial visit.

12. **Ultrasound**: An early ultrasound can confirm gestational age, detect multiple pregnancies, and identify potential complications early on.

13. **Glucose Screening**: Although typically performed between 24 and 28 weeks of gestation, discussing the risk factors for gestational diabetes and planning for the glucose screening test can be part of the initial prenatal visit.

It's essential to note that the specific tests and screenings may vary based on individual risk factors, local health guidelines, and the healthcare provider's recommendations. This visit is also an opportunity to discuss healthy pregnancy habits, nutrition, and any concerns the patient or her husband may have.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 33-year-old HIV-positive male is seen in clinic 
Given the patient's history of depression and non-adherence to his HIV medications, it's essential to address both his mental health and the increased risk of opportunistic infections due to his low CD4+ count.

In addition to restarting his anti-retroviral therapy (ART), the patient should be considered for the following medications:

1. **Prophylaxis against opportunistic infections**: With a CD4+ count of 33 cells/mm3, the patient is at high risk for opportunistic infections such as Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and cryptococcosis. Prophylactic medications may include:
	* Trimethoprim-sulfamethoxazole (TMP-SMX) for PCP prophylaxis.
	* Other options may include dapsone, atovaquone, or pentamidine, depending on the patient's specific needs and medical history.
2. **Antidepressant medication**: To address the patient's depression, an antidepressant medication should be prescribed. Selective serotonin reuptake inhibitors (SSRIs) are commonly used in patients with HIV, as they are generally well-tolerated and effective. Examples include:
	* Fluoxetine (Prozac)
	* Sertraline (Zoloft)
	* Paroxetine (Paxil)
3. **Other considerations**: Depending on the patient's specific needs, other medications may be necessary, such as:
	* Azithromycin for prophylaxis against Mycobacterium avium complex (MAC) infection, which is recommended for patients with CD4+ counts < 50 cells/mm3.

It's essential to note that the patient's ART regimen should be restarted as soon as possible, and the patient should be closely monitored for adherence and response to treatment. The patient's mental health should also be closely monitored, and the antidepressant medication should be adjusted as needed to ensure optimal management of his depression.

A multidisciplinary approach, including a primary care provider, an HIV specialist, a mental health professional, and a social worker, may be necessary to address the patient's complex medical and psychosocial needs.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 30-year-old woman with HIV comes to the emergenc
Based on the clinical presentation and biopsy results, the most likely diagnosis is Bacillary Angiomatosis (BA), a condition caused by the bacteria Bartonella henselae or Bartonella quintana. BA is a common opportunistic infection in patients with advanced HIV disease, particularly those with low CD4+ T-lymphocyte counts.

The most appropriate pharmacotherapy for Bacillary Angiomatosis is:

1. **Erythromycin**: This is the first-line treatment for BA. The recommended dose is 500 mg orally four times a day for at least 3 months.
2. **Doxycycline**: This is an alternative treatment option, particularly for patients who are intolerant to erythromycin. The recommended dose is 100 mg orally twice a day for at least 3 months.

It's essential to note that the patient's HIV infection and low CD4+ T-lymphocyte count also need to be addressed. Antiretroviral therapy (ART) should be initiated or optimized to improve the patient's immune function and prevent further opportunistic infections.

In addition to treating the BA, the patient's other health issues, such as malnutrition (BMI 19 kg/m2), smoking, and substance abuse, should also be addressed to improve her overall health and well-being.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 35-year-old man comes to the physician because o
Based on the treatment regimen started, which includes lamivudine, zidovudine, and indinavir, the patient is at greatest risk for the following adverse effects:

1. **Lactic acidosis and hepatotoxicity**: Lamivudine and zidovudine, both nucleoside reverse transcriptase inhibitors (NRTIs), can cause lactic acidosis and hepatotoxicity, although this is more commonly associated with other NRTIs like stavudine and didanosine.
2. **Bone marrow suppression**: Zidovudine can cause bone marrow suppression, leading to anemia, neutropenia, and thrombocytopenia.
3. **Nephrolithiasis**: Indinavir, a protease inhibitor, can cause nephrolithiasis (kidney stones) due to its low solubility in urine.
4. **Hyperbilirubinemia**: Indinavir can also cause hyperbilirubinemia (elevated bilirubin levels), which may lead to jaundice.
5. **Lipodystrophy**: The combination of lamivudine, zidovudine, and indinavir may increase the risk of lipodystrophy (abnormal fat distribution), which can lead to changes in body shape and metabolic abnormalities.
6. **Gastrointestinal symptoms**: All three medications can cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain.
7. **Increased risk of cardiovascular events**: Protease inhibitors, including indinavir, have been associated with an increased risk of cardiovascular events, such as myocardial infarction and stroke.

It's essential to note that the patient's CD4 count is relatively high (600 cells/μl), and the viral load is relatively low (104 copies/mL), which may indicate that the patient is in the early stages of HIV infection. The treatment regimen should be closely monitored, and the patient should be educated about the potential adverse effects and the importance of adherence to the treatment regimen.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 52-year-old man is brought to the emergency depa
Based on the patient's symptoms, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).

Here's why:

1. **HIV-positive status with low CD4+ count**: The patient has a history of HIV and a low CD4+ count (90/μL), which increases his risk for opportunistic infections and malignancies, including PCNSL.
2. **Neurological symptoms**: The patient presents with headaches, vertigo, changes in personality, ataxia, and apathy, which are consistent with a brain lesion.
3. **Ring-enhancing lesion on MRI**: The solitary ring-enhancing lesion involving the corpus callosum is a characteristic feature of PCNSL, particularly in immunocompromised patients.
4. **Positive Epstein-Barr virus (EBV) DNA PCR in CSF**: EBV is associated with PCNSL, especially in HIV-positive patients. The presence of EBV DNA in the cerebrospinal fluid (CSF) supports the diagnosis of PCNSL.
5. **Slight pleocytosis in CSF**: The presence of slight pleocytosis (increased cell count) in the CSF is consistent with PCNSL.

While other diagnoses, such as toxoplasmosis or progressive multifocal leukoencephalopathy (PML), are possible in an HIV-positive patient with a brain lesion, the combination of the patient's symptoms, imaging findings, and positive EBV DNA PCR in CSF makes PCNSL the most likely diagnosis.

It's worth noting that PCNSL is a rare and aggressive malignancy that requires prompt treatment, usually with chemotherapy and/or radiation therapy.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 2300-g (5-lb 1-oz) male newborn is delivered to 
The most appropriate next step in the management of this infant, born to an HIV-positive mother, is to initiate antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV. This is a critical step, even though the mother received triple antiretroviral therapy during pregnancy, because the viral load was detectable (678 copies/mL) close to the time of delivery. The goal of antiretroviral prophylaxis in the newborn is to further reduce the risk of HIV transmission from mother to child.

The recommended regimen for the newborn typically involves the administration of zidovudine (AZT) monotherapy for a period of 4 to 6 weeks, starting as soon as possible after birth, ideally within the first 6-12 hours of life. This is in accordance with guidelines from health organizations such as the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP), which aim to minimize the risk of HIV transmission.

Additionally, the following steps should be considered:

1. **HIV Testing:** The infant should undergo HIV testing, including virologic tests (such as HIV DNA or RNA PCR) at birth (or as soon as possible), at 14-21 days, 1-2 months, and 4-6 months of age. Antibody tests are not useful in the first 18 months of life due to the presence of maternal antibodies.

2. **Clinical Monitoring:** Regular follow-up with a pediatrician experienced in the care of HIV-exposed infants is crucial. This includes monitoring for signs of HIV infection and assessing the infant's overall health and development.

3. **Avoidance of HIV Post-Exposure Prophylaxis (PEP) for Breastfeeding:** Since the mother is HIV-positive, breastfeeding is generally not recommended in settings where safe alternatives are readily available, to prevent postnatal transmission of HIV.

4. **Support and Counseling:** The family should receive counseling and support regarding the infant's care, the importance of adherence to the antiretroviral prophylaxis regimen, and follow-up appointments.

It's essential to manage the care of the HIV-exposed infant in consultation with a pediatric HIV specialist or an experienced pediatrician, as the specifics of care can vary based on the most current guidelines and the individual circumstances of the case.
Saved Llama answers (category=4, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_4.1_HIV_EQ.json
API call for Meditron failed with error: Connection error.
Falling back to local Meditron inference - Loading model...
Loading checkpoint shards:   0%|                                                                                                                                                                             | 0/30 [00:00<?, ?it/s]Loading checkpoint shards:   3%|█████▌                                                                                                                                                               | 1/30 [00:13<06:29, 13.42s/it]Loading checkpoint shards:   7%|███████████                                                                                                                                                          | 2/30 [01:19<20:41, 44.34s/it]Loading checkpoint shards:  10%|████████████████▌                                                                                                                                                    | 3/30 [01:26<12:19, 27.39s/it]Loading checkpoint shards:  13%|██████████████████████                                                                                                                                               | 4/30 [01:30<07:51, 18.12s/it]Loading checkpoint shards:  17%|███████████████████████████▌                                                                                                                                         | 5/30 [02:05<10:08, 24.35s/it]Loading checkpoint shards:  20%|█████████████████████████████████                                                                                                                                    | 6/30 [02:21<08:35, 21.47s/it]Loading checkpoint shards:  23%|██████████████████████████████████████▌                                                                                                                              | 7/30 [02:23<05:47, 15.12s/it]Loading checkpoint shards:  27%|████████████████████████████████████████████                                                                                                                         | 8/30 [02:28<04:17, 11.71s/it]Loading checkpoint shards:  30%|█████████████████████████████████████████████████▌                                                                                                                   | 9/30 [02:30<03:05,  8.84s/it]Loading checkpoint shards:  33%|██████████████████████████████████████████████████████▋                                                                                                             | 10/30 [02:31<02:08,  6.43s/it]Loading checkpoint shards:  37%|████████████████████████████████████████████████████████████▏                                                                                                       | 11/30 [02:36<01:49,  5.79s/it]Loading checkpoint shards:  40%|█████████████████████████████████████████████████████████████████▌                                                                                                  | 12/30 [02:39<01:33,  5.19s/it]Loading checkpoint shards:  43%|███████████████████████████████████████████████████████████████████████                                                                                             | 13/30 [02:42<01:14,  4.40s/it]Loading checkpoint shards:  47%|████████████████████████████████████████████████████████████████████████████▌                                                                                       | 14/30 [02:44<00:56,  3.53s/it]Loading checkpoint shards:  50%|██████████████████████████████████████████████████████████████████████████████████                                                                                  | 15/30 [02:44<00:38,  2.54s/it]Loading checkpoint shards:  53%|███████████████████████████████████████████████████████████████████████████████████████▍                                                                            | 16/30 [02:45<00:29,  2.08s/it]Loading checkpoint shards:  57%|████████████████████████████████████████████████████████████████████████████████████████████▉                                                                       | 17/30 [02:45<00:19,  1.54s/it]Loading checkpoint shards:  60%|██████████████████████████████████████████████████████████████████████████████████████████████████▍                                                                 | 18/30 [02:48<00:21,  1.81s/it]Loading checkpoint shards:  63%|███████████████████████████████████████████████████████████████████████████████████████████████████████▊                                                            | 19/30 [02:48<00:14,  1.33s/it]Loading checkpoint shards:  67%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████▎                                                      | 20/30 [02:48<00:09,  1.00it/s]Loading checkpoint shards:  70%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████▊                                                 | 21/30 [02:50<00:11,  1.27s/it]Loading checkpoint shards:  73%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▎                                           | 22/30 [02:52<00:11,  1.39s/it]Loading checkpoint shards:  77%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▋                                      | 23/30 [02:52<00:08,  1.17s/it]Loading checkpoint shards:  80%|███████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▏                                | 24/30 [02:52<00:05,  1.12it/s]Loading checkpoint shards:  83%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▋                           | 25/30 [02:56<00:08,  1.70s/it]Loading checkpoint shards:  87%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▏                     | 26/30 [02:56<00:05,  1.25s/it]Loading checkpoint shards:  90%|███████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▌                | 27/30 [02:58<00:04,  1.50s/it]Loading checkpoint shards:  93%|█████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████           | 28/30 [02:59<00:02,  1.19s/it]Loading checkpoint shards:  97%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████▌     | 29/30 [03:04<00:02,  2.30s/it]Loading checkpoint shards: 100%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 30/30 [03:05<00:00,  1.85s/it]Loading checkpoint shards: 100%|████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 30/30 [03:05<00:00,  6.17s/it]
Some parameters are on the meta device because they were offloaded to the cpu.
Starting inference for question locally (Meditron): How is HIV diagnosed?
slurmstepd: error: *** STEP 20959321.0 ON eu-a65-07 CANCELLED AT 2025-01-16T16:08:09 ***
slurmstepd: error: *** JOB 20959321 ON eu-a65-07 CANCELLED AT 2025-01-16T16:08:09 ***
W0116 16:08:09.189000 23063529457472 torch/distributed/elastic/agent/server/api.py:741] Received 15 death signal, shutting down workers
W0116 16:08:09.189000 23063529457472 torch/distributed/elastic/multiprocessing/api.py:851] Sending process 1647338 closing signal SIGTERM
